Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 4/20 | 0.48 |
| ▸ | SELP | P16109 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | SELE | P16581 | 4/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | AMY2A | P04746 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
| ▸ | BDNF | P23560 | 2/20 | 0.39 |
| ▸ | PTN | P21246 | 1/20 | 0.39 |
| ▸ | MDK | P21741 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30478259 | 0.89 | MAPK1 (0.52) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL12203873 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL20516505 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL29401384 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL14268511 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL11505202 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL20516519 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL21128354 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL10086040 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 | |
| SCHEMBL29353032 | 0.89 | LGALS3 (0.55) | SELLSELPMAPK1LGALS3LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| CN-117815381-A | Carbohydrate modified particles and particle formulations for modulating immune responses | 西北大学 | 2024-04-05 | — | — | CN | claimed |
| US-20230277607-A1 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | ACARYON GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20230058412-A1 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | NORTHWESTERN UNIVERSITY | 2023-02-23 | — | — | US | claimed |
| US-12227788-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | TUMOREND, LLC (US) | 2025-02-18 | — | — | US | disclosed |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2025-01-07 | — | — | US | disclosed |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | disclosed |
| CN-117815381-A | Carbohydrate modified particles and particle formulations for modulating immune responses | 西北大学 | 2024-04-05 | — | — | CN | disclosed |
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | KODE BIOTECH LIMITED (NZ) | 2023-11-23 | — | — | US | disclosed |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2023-09-19 | — | — | US | disclosed |
| US-20230277607-A1 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | ACARYON GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| CN-116568810-A | Novel anti-sugar chain antibody and use thereof | 国立大学法人千叶大学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023113596-A1 | DIAGNOSIS AND TREATMENT OF COLORECTAL CANCER | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2023-06-22 | — | — | WO | disclosed |
| US-20230058412-A1 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | NORTHWESTERN UNIVERSITY | 2023-02-23 | — | — | US | disclosed |
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | TUMOREND, LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3975723-A1 | DEVICE AND METHOD FOR DECONTAMINATION/DISINFECTION | Aquila Bioscience Limited (IE) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | SIGLEC7, SIGLEC9, HAVCR2 | SELL 35/4885SELP 21/4885MAPK1 3021/4885 |
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | SGMS1, SGMS2, CERT1 | SELL 186/4885SELP 227/4885MAPK1 4360/4885 |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | SELL 287/4885SELP 332/4885MAPK1 4286/4885 |
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | SELL 336/4885SELP 241/4885MAPK1 3425/4885 |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | SELL 310/4885SELP 337/4885MAPK1 4299/4885 |
| US-12227788-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | SIGLEC7, SIGLEC9, HAVCR2 | SELL 35/4885SELP 21/4885MAPK1 3021/4885 |
| US-20230277607-A1 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | UGCG, CERT1, SGMS2 | SELL 1024/4885SELP 1875/4885MAPK1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.